register free | resend password


Prima BioMed Announces First Clinical Data From Combination of IMP321 With Anti-PD1

ID: 1477912
recent pressrelease next pressrelease

(businesspress24) - SYDNEY, AUSTRALIA -- (Marketwired) -- 12/29/16 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima" or the "Company") today announced interim data for its TACTI-mel (Two ACTive Immunotherapeutics in melanoma) clinical trial program for IMP321 in unresectable or metastatic melanoma patients. The Database Safety Monitoring Board (DSMB) confirmed that IMP321 is safe and well tolerated at the first dose level when used in combination with a PD-1 blocking antibody and dose escalation can continue as planned.

In this first-in-man combination Phase I study, IMP321 is combined with the PD-1 checkpoint inhibitor pembrolizumab (KEYTRUDA®). Patients with unresectable or metastatic melanoma that had suboptimal or no responses to KEYTRUDA have been receiving IMP321 plus KEYTRUDA to help boost their immune responses and increase the tumour response rate to KEYTRUDA. Initial data show no safety concerns from the combination with IMP321 at 1 mg dosage. No drug related serious adverse events have been reported and the DSMB approved the continuance of the dose escalation as planned. The trial will now proceed to the next dose level of 6 mg.

Prima''s Chief Medical Officer, Dr Frédéric Triebel, said: "The majority of metastatic melanoma patients do not respond well to KEYTRUDA, a key reason being that their tumours are poorly infiltrated by activated T cells expressing PD-1. By introducing IMP321, a first-in-class Antigen Presenting Cell (APC) activator, these patients may now be able to repopulate their tumour with more activated T cells which are responsive to KEYTRUDA. So, by combining the effect of ''pushing the gas'' with IMP321 and ''releasing the brake'' with KEYTRUDA we propose a rational therapeutic approach to increase the response rate by further boosting anti-tumour CD8 T cells."

Further data updates in terms of safety and activity could be expected throughout 2017.

IMP321, a first-in-class Antigen Presenting Cell (APC) activator based on the immune checkpoint LAG-3, represents one of the first proposed active immunotherapy drugs in which the patient''s own immune system is harnessed to respond to tumour antigenic debris created by chemotherapy. As an APC activator IMP321 boosts the network of dendritic cells in the body that can respond to tumour antigens for a better anti-tumour CD8 T cell response.

Prima BioMed is listed on the Australian Securities Exchange and on the NASDAQ in the US. For further information please visit .

Matthew Beck


The Trout Group LLC
+1 (646) 378-2933


Mr Matthew Gregorowski
Citadel-MAGNUS
+61 2 8234 0105



More information:
https://opensourceorganics.com http://www.callrogersplumbing.com http://www.mss-software.com http://primerealtyinc.com/ http://www.writingaliteraturereview.com



Keywords (optional):

prima-biomed-ltd,



Company information / Profile:

PressRelease by

Requests:



PressContact / Agency:



published by: Marketwired
print pressrelease  send to a friend  

Date: 12/29/2016 - 09:04
Language: English
News-ID 1477912
Character count: 2267
Kontakt-Informationen:
Firma: Prima BioMed Ltd
Ansprechpartner: Feedback to businesspress24.com about Pressrelease-id:
Stadt: SYDNEY, AUSTRALIA
Telefon:

Meldungsart:
Versandart:
Freigabedatum:
Comments:



Number of hits: 215

Linking-Tips:



Direct Link to this PressRelease:






We would appreciate a link in your News-, Press- or Partner-Site.

Comments on this PressRelease






All members: 9 408
Register today: 0
Register yesterday: 2
Members online: 0
Guests online: 58


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.